Search research articles
Contact Us
Filters
Showing results (21-30 of 51) with videos related to
Page
of 6
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
December 14, 2004
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
Michael J Detke, Curtis G Wiltse, Craig H Mallinckrodt, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
July 27, 2010
Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study
Istvan Bitter, Tamás Treuer, Nesrin Dilbaz, et al.
Journal of Affective Disorders
|
December 5, 2024
Comparison of overall survival and healthcare resource utilization among patients with major depressive disorder with or without psychiatric emergency admission: A real-world study from Hungary
Zoltan Rihmer, Peter Dome, Gyorgy Szekeres, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
September 30, 2024
Mortality in patients with major depressive disorder: A nationwide population-based cohort study with 11-year follow-up
Istvan Bitter, Gyorgy Szekeres, Qian Cai, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
January 30, 2025
Developing the EPA guidance of pharmacological treatment of schizophrenia - results of a Delphi process
Peter Falkai, Elias Wagner, Miriam John, et al.
The Journal of Clinical Psychiatry
|
April 21, 2004
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol
Martin Dossenbach, Almila Erol, Mohand el Mahfoud Kessaci, et al.
Neuroscience Applied
|
June 8, 2026
Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurement
Armida Mucci, Michael Davidson, Silvia Zaragoza Domingo, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
March 2, 2019
Randomized, double-blind, placebo-controlled study of F17464, a preferential D<sub>3</sub> antagonist, in the treatment of acute exacerbation of schizophrenia
Istvan Bitter, Jeffrey A Lieberman, Florence Gaudoux, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
December 23, 2003
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
Istvan Bitter, Martin R K Dossenbach, Shlomo Brook, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
July 2, 2024
Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression
Roger S McIntyre, Istvan Bitter, Jozefien Buyze, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 51) with videos related to
Sort By:
Page
of 6
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
December 14, 2004
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
Michael J Detke, Curtis G Wiltse, Craig H Mallinckrodt, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
July 27, 2010
Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study
Istvan Bitter, Tamás Treuer, Nesrin Dilbaz, et al.
Journal of Affective Disorders
|
December 5, 2024
Comparison of overall survival and healthcare resource utilization among patients with major depressive disorder with or without psychiatric emergency admission: A real-world study from Hungary
Zoltan Rihmer, Peter Dome, Gyorgy Szekeres, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
September 30, 2024
Mortality in patients with major depressive disorder: A nationwide population-based cohort study with 11-year follow-up
Istvan Bitter, Gyorgy Szekeres, Qian Cai, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
January 30, 2025
Developing the EPA guidance of pharmacological treatment of schizophrenia - results of a Delphi process
Peter Falkai, Elias Wagner, Miriam John, et al.
The Journal of Clinical Psychiatry
|
April 21, 2004
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol
Martin Dossenbach, Almila Erol, Mohand el Mahfoud Kessaci, et al.
Neuroscience Applied
|
June 8, 2026
Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurement
Armida Mucci, Michael Davidson, Silvia Zaragoza Domingo, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
March 2, 2019
Randomized, double-blind, placebo-controlled study of F17464, a preferential D<sub>3</sub> antagonist, in the treatment of acute exacerbation of schizophrenia
Istvan Bitter, Jeffrey A Lieberman, Florence Gaudoux, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
December 23, 2003
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
Istvan Bitter, Martin R K Dossenbach, Shlomo Brook, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
July 2, 2024
Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression
Roger S McIntyre, Istvan Bitter, Jozefien Buyze, et al.
Page
of 6